IL277858B1 - Antibodies specific for human nectin-4 - Google Patents

Antibodies specific for human nectin-4

Info

Publication number
IL277858B1
IL277858B1 IL277858A IL27785820A IL277858B1 IL 277858 B1 IL277858 B1 IL 277858B1 IL 277858 A IL277858 A IL 277858A IL 27785820 A IL27785820 A IL 27785820A IL 277858 B1 IL277858 B1 IL 277858B1
Authority
IL
Israel
Prior art keywords
antibodies specific
human nectin4
nectin4
human
antibodies
Prior art date
Application number
IL277858A
Other languages
English (en)
Hebrew (he)
Other versions
IL277858A (en
Inventor
Mandelboim Ofer
Tsukerman Pinchas
Jonjic Stipan
Reches Adi
Original Assignee
Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd
Nectin Therapeutics Ltd
Mandelboim Ofer
Tsukerman Pinchas
Jonjic Stipan
Reches Adi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd, Nectin Therapeutics Ltd, Mandelboim Ofer, Tsukerman Pinchas, Jonjic Stipan, Reches Adi filed Critical Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd
Publication of IL277858A publication Critical patent/IL277858A/en
Publication of IL277858B1 publication Critical patent/IL277858B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4254—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/563—Immunoassay; Biospecific binding assay; Materials therefor involving antibody fragments
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
IL277858A 2018-05-09 2019-05-06 Antibodies specific for human nectin-4 IL277858B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862668824P 2018-05-09 2018-05-09
PCT/IL2019/050508 WO2019215728A1 (en) 2018-05-09 2019-05-06 Antibodies specific to human nectin4

Publications (2)

Publication Number Publication Date
IL277858A IL277858A (en) 2020-11-30
IL277858B1 true IL277858B1 (en) 2026-04-01

Family

ID=66690730

Family Applications (1)

Application Number Title Priority Date Filing Date
IL277858A IL277858B1 (en) 2018-05-09 2019-05-06 Antibodies specific for human nectin-4

Country Status (9)

Country Link
US (2) US12077583B2 (enExample)
EP (1) EP3790900A1 (enExample)
JP (2) JP2021522801A (enExample)
KR (2) KR102892725B1 (enExample)
CN (2) CN112088167B (enExample)
AU (1) AU2019264965B2 (enExample)
CA (1) CA3097679A1 (enExample)
IL (1) IL277858B1 (enExample)
WO (1) WO2019215728A1 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
CN113614109A (zh) 2018-12-21 2021-11-05 Ose免疫疗法公司 双功能抗pd-1/il-7分子
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
AU2020406083A1 (en) 2019-12-17 2022-06-16 Boehringer Ingelheim International Gmbh Bifunctional molecules comprising an IL-7 variant
WO2021168274A1 (en) 2020-02-21 2021-08-26 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
CN113527486B (zh) * 2020-04-21 2025-12-02 迈威(上海)生物科技股份有限公司 一种抗Nectin-4的抗体及其应用
CA3176497A1 (en) 2020-05-07 2021-11-11 Fatima MECHTA-GRIGORIOU Antxr1 as a biomarker of immunosuppressive fibroblast populations and its use for predicting response to immunotherapy
CN115768798A (zh) * 2020-06-18 2023-03-07 生物蛋白有限公司 条件活性抗粘附分子-4(nectin-4)抗体
EP4208259A2 (en) * 2020-09-04 2023-07-12 NovaRock Biotherapeutics, Ltd. Nectin-4 antibodies and uses thereof
CN117285629A (zh) * 2020-09-16 2023-12-26 四川科伦博泰生物医药股份有限公司 抗Nectin-4抗体、包含所述抗体的缀合物及其应用
WO2022112198A1 (en) 2020-11-24 2022-06-02 Worldwide Innovative Network Method to select the optimal immune checkpoint therapies
WO2022148781A1 (en) 2021-01-05 2022-07-14 Institut Curie Combination of mcoln activators and immune checkpoint inhibitors
WO2022214653A1 (en) 2021-04-09 2022-10-13 Ose Immunotherapeutics New scaffold for bifunctional molecules with improved properties
US20240182572A1 (en) 2021-04-09 2024-06-06 Ose Immunotherapeutics Scaffold for bifunctional molecules comprising pd-1 or cd28 and sirp binding domains
BR112023022098A2 (pt) * 2021-04-26 2023-12-19 Jiangsu Hengrui Pharmaceuticals Co Ltd Anticorpo anti-nectina-4 e conjugado anticorpo-fármaco anti-nectina-4 e uso medicinal dos mesmos
EP4363453A4 (en) * 2021-06-29 2025-06-11 Elpis Biopharmaceuticals ANTI-NECTIN4 ANTIBODIES AND MULTISPECIFIC PROTEIN COMPLEXES
CA3227845A1 (en) * 2021-07-30 2023-02-02 R.P. Scherer Technologies, Llc Antibody-drug conjugates and methods of use thereof
AU2022335573C1 (en) * 2021-08-27 2026-02-19 CSPC Megalith Biopharmaceutical Co., Ltd. Anti-nectin-4 antibody, drug conjugate, and preparation method therefor and use thereof
CA3242471A1 (en) * 2022-01-12 2023-07-20 Navi Bio-Therapeutics, Inc. Antibody specific to nectin cell adhesion molecule 4 and uses thereof
EP4496593A1 (en) 2022-03-23 2025-01-29 Synaffix B.V. Antibody-conjugates for targeting of tumours expressing nectin-4
WO2023198007A1 (en) * 2022-04-11 2023-10-19 Bj Bioscience Inc. Anti-nectin-4 antibodies and bispecific antibodies
WO2023198011A1 (en) * 2022-04-11 2023-10-19 Bj Bioscience Inc. Single domain anti-nectin-4 antibodies
CN116063498A (zh) * 2022-04-27 2023-05-05 博际生物医药科技(杭州)有限公司 单域抗Nectin-4抗体
WO2024003360A1 (en) 2022-07-01 2024-01-04 Institut Curie Biomarkers and uses thereof for the treatment of neuroblastoma
EP4565610A1 (en) 2022-08-02 2025-06-11 Ose Immunotherapeutics Multifunctional molecule directed against cd28
US20260091114A1 (en) * 2022-09-14 2026-04-02 Fred Hutchinson Cancer Center Chimeric antigen receptors binding nectin-4
US20260014269A1 (en) 2022-09-20 2026-01-15 Nectin Therapeutics Ltd. Humanized antibodies against nectin-4 and drug conjugates thereof
AU2023375625A1 (en) * 2022-11-10 2025-05-15 Century Therapeutics, Inc. Genetically engineered cells having anti-nectin4 chimeric antigen receptors, and uses thereof
EP4646267A1 (en) * 2023-01-03 2025-11-12 Harpoon Therapeutics, Inc. Nectin4 targeting trispecific protein for treatment of cancer
CN116381251B (zh) * 2023-03-13 2024-06-25 柏定生物工程(北京)有限公司 一种肿瘤标志物诊断试剂盒及其诊断方法
JP2026512425A (ja) 2023-03-30 2026-04-16 オーエスイー・イミュノセラピューティクス 免疫細胞増強分子の発現のための活性化免疫細胞に標的化された脂質ベースのナノ粒子及びその使用
EP4687990A1 (en) 2023-03-30 2026-02-11 Ose Immunotherapeutics Method of synthesis of targeted lipid nanoparticle and uses thereof
CN119490590A (zh) * 2023-05-24 2025-02-21 深圳市先康达生命科学有限公司 靶向人Nectin4蛋白的抗体或其片段和应用
EP4725964A1 (en) * 2023-06-08 2026-04-15 Jiangsu Mabwell Health Pharmaceutical R&D Co., Ltd. Antibody binding to nectin-4 and use thereof
WO2025068461A1 (en) 2023-09-29 2025-04-03 Negio Therapeutics Guanfacine derivatives and their use in treating cancer
WO2025068452A1 (en) 2023-09-29 2025-04-03 Negio Therapeutics Guanfacine derivatives and their use in treating cancer
WO2025132831A1 (en) 2023-12-19 2025-06-26 Universite D'aix-Marseille N-heteroaryl derivatives and uses thereof for treating cancer
WO2025240789A1 (en) * 2024-05-16 2025-11-20 The Regents Of The University Of California Chimeric antigen receptor targeting nectin4
WO2025242835A1 (en) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of cancer
WO2025242836A1 (en) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of auto-immune or inflammatory diseases and disorders
WO2025262250A1 (en) 2024-06-20 2025-12-26 Negio Therapeutics Guanfacine derivatives and their uses
WO2026068705A1 (en) 2024-09-26 2026-04-02 Ose Immunotherapeutics Lipid-based nanoparticles comprising non-glycosylated fc domains and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017042210A1 (en) * 2015-09-09 2017-03-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to nectin-4 and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4198507A (en) 1978-11-13 1980-04-15 Hoffmann-La Roche Inc. Theophylline magnesium salicylate
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
ES2102007T3 (es) 1992-01-23 1997-07-16 Merck Patent Gmbh Proteinas de fusion de fragmentos de anticuerpo monomeras y dimeras.
JP3659261B2 (ja) 1994-10-20 2005-06-15 モルフォシス・アクチェンゲゼルシャフト 組換体タンパク質の多機能性複合体への標的化ヘテロ結合
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
ATE274064T1 (de) 1995-05-23 2004-09-15 Morphosys Ag Multimere proteine
US5719867A (en) 1995-06-30 1998-02-17 Scientific-Atlanta, Inc. Plural telephony channel baseband signal demodulator for a broadband communications system
EP1103181A1 (de) 1999-11-25 2001-05-30 Novartis AG Kombination der N-Phenyl-N'-Benzoyl Harnstoff Derivaten und Avermectin für Parasiten Kontrolle.
EP1481993A1 (en) 2003-05-28 2004-12-01 Xerion Pharmaceuticals AG Modulation of the poliovirus receptor function
US20090214517A1 (en) 2004-07-27 2009-08-27 Justin Wong Compositions and methods of use for modulators of nectin 4, semaphorin 4b, igsf9, and kiaa0152 in treating disease
CA2672581A1 (en) * 2006-12-14 2008-06-19 Forerunner Pharma Research Co., Ltd. Anti-claudin 3 monoclonal antibody and treatment and diagnosis of cancer using the same
US9399062B2 (en) * 2011-01-18 2016-07-26 Christopher D. Richardson PVRL4 (Nectin4) is a receptor for measles virus
AU2013355379B2 (en) 2012-12-04 2018-08-09 Oncomed Pharmaceuticals, Inc. Immunotherapy with binding agents
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
CR20170060A (es) 2014-08-19 2017-04-18 Merck Sharp & Dohme Anticuerpos anti tigit
SG11201706583PA (en) 2015-02-19 2017-09-28 Compugen Ltd Anti-pvrig antibodies and methods of use
EP3344658B1 (en) 2015-09-02 2022-05-11 Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. Antibodies specific to human t-cell immunoglobulin and itim domain (tigit)
KR20250065434A (ko) 2016-03-01 2025-05-12 이섬 리서치 디벨러프먼트 컴파니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. 인간 폴리오바이러스 수용체(ｐｖｒ)에 특이적인 항체
EP3589654A1 (en) 2017-03-02 2020-01-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to nectin-4 and uses thereof
WO2022056304A1 (en) 2020-09-10 2022-03-17 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using nectin-4 specific fusion proteins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017042210A1 (en) * 2015-09-09 2017-03-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to nectin-4 and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CAMPBELL DEAN O ET AL,, PRECLINICAL EVALUATION OF AN ANTI-NECTIN-4 IMMUNOPET REAGENT IN TUMOR-BEARING MICE AND BIODISTRIBUTION STUDIES IN CYNOMOLGUS MONKEYS, 27 April 2016 (2016-04-27) *
P. M. CHALLITA-EID ET AL,, ENFORTUMAB VEDOTIN ANTIBODY-DRUG CONJUGATE TARGETING NECTIN-4 IS A HIGHLY POTENT THERAPEUTIC AGENT IN MULTIPLE PRECLINICAL CANCER MODELS, 15 May 2016 (2016-05-15) *
PAVLOVA N N ET AL,, A ROLE FOR PVRL4-DRIVEN CELL-CELL INTERACTIONS IN TUMORIGENESIS, 30 April 2013 (2013-04-30) *

Also Published As

Publication number Publication date
AU2019264965A1 (en) 2020-11-19
US12077583B2 (en) 2024-09-03
CN112088167B (zh) 2025-01-10
KR102892725B1 (ko) 2025-12-01
EP3790900A1 (en) 2021-03-17
AU2019264965B2 (en) 2025-08-21
CA3097679A1 (en) 2019-11-14
US20240376202A1 (en) 2024-11-14
CN112088167A (zh) 2020-12-15
CN119823267A (zh) 2025-04-15
IL277858A (en) 2020-11-30
JP2021522801A (ja) 2021-09-02
KR20210009308A (ko) 2021-01-26
JP2024088696A (ja) 2024-07-02
US20210130459A1 (en) 2021-05-06
KR20250173584A (ko) 2025-12-10
WO2019215728A1 (en) 2019-11-14

Similar Documents

Publication Publication Date Title
IL277858A (en) Antibodies specific for human nectin-4
ZA201905341B (en) Antibodies specifically binding to human il-1r7
IL276537A (en) Antibodies bind to GPRC5D
IL261188A (en) Antibodies against tigit
IL325604A (en) New anti-CD3 epsilon antibodies
HRP20181802T1 (hr) Protutijela koja vežu humani cd3
IL270244A (en) Antibody against human semaphorin 4D
IL246661B (en) Human antibodies to pd–l1
TWI563003B (en) Human anti-il-33 neutralization monoclonal antibody
SG11201608567YA (en) Human antibodies to middle east respiratory syndrome -coronavirus spike protein
PT3390451T (pt) Anticorpos humanos caninizados para il-4r alfa humano e canino
IL271128A (en) New anti-3cd antibodies
IL269394A (en) Antibodies bind to STEAP-1
ZA202104356B (en) Monoclonal antibodies that bind specifically to human trbv9
HUE055189T2 (hu) Humán monoklonális antitestek a GD2 ganglioziddal ellen
EP3551228A4 (en) ANTIBODIES FOR HUMAN ALPHA SYNUCLEIN
PT3101132T (pt) Anticorpo humano anti-transtirretina
GB201720970D0 (en) Antibodies
PL3180356T3 (pl) Ludzkie przeciwciało anty-fgfr4
EP3323832A4 (en) Antibody which specifically binds to human crth2
IL269318A (en) Antibodies to human erythroperone and uses thereof
GB201609742D0 (en) Improvements relating to antibodies
IL272015A (en) Antibodies to MADCAM
HK40029215A (zh) 结合ror2的人抗体
GB201820547D0 (en) Modified antibodies